Biocontrol Limited

Evolution Biotechnologies Ltd.

Armata Pharmaceuticals, Inc.

David R Harper

Catherine Hawkins

James Soothill

Katy Blake

Catherine Dept Of Medical Microbiology Hawkins

James Dept Of Medical Microbiology Soothill

The present invention relates to a method of treating or preventing a house dust mite infestation, said method comprising applying an acaricidal infectious agent at a site of a house dust mite infestation, or at a site proximal thereto, or at a site at risk of such infestation. Also encompassed are uses of acaricidal infectious agents, methods of isolating acaricidal infectious agents, acaricidal infectious agents obtainable by said methods, acaricidal infectious agent formulations, foodstuffs and mite attractants comprising the same.

Acaricides

The present invention provides methods of designing panels of bacteriophages as therapeutic compositions against bacterial infections. The present invention also provides panels of bacteriophages for use in the prevention or treatment of bacterial infections.

Therapeutic bacteriophage compositions

The present invention relates in its broadest aspect to combined phage/antibiotic therapy. More particularly, it relates to use of (i) one or more bacteriophages and (ii) one or more antibiotics in the manufacture of a combined product for simultaneous, separate or sequential administration of (i) and (ii) to treat a bacterial infection characterized by biofilm formation, for example an infection comprising or consisting of. Treatment in this context may be either therapeutic or prophylactic treatment. Also provided are deposited bacteriophages each exhibiting different strain specificity againstand combinations of such bacteriophages, e.g. a panel of six deposited bacteriophages which was found to be effective against a high percentage of clinical isolates offrom canine ear infections.

Bacteriophage-containing therapeutic agents

The invention relates to use of one or more bacteriophages in vivo in a human or animal in order to induce sensitivity to chemical antibiotics in bacterial cells, where such susceptibility is heritable, independent of continuing bacteriophage metabolism within those cells, and does not relate to the destruction of a biofilm to induce such sensitivity.

Growing community of inventors

Sharnbrook, United Kingdom

David R Harper